UPDATE: Deutsche Bank Raises Target to $66 on Gilead Sciences - Gilead Sciences (NASDAQ:GILD)

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

Deutsche Bank maintains its Buy rating on Gilead Sciences (NASDAQ: GILD) and raises its price target to $66 from $53 a share as it believes shares on increased confidence in HCV.Deutsche Bank says, "We see Gilead as one of our top picks in large cap biotech, with above-average growth opportunities (‘12-‘18 revenue CAGR of 22%)and a series of HCV & HIV catalysts in 2012. We believe the street is underestimating the market oppy for ‘7977 in HCV as well as the ability of Gilead to take majority new HIV patient market share with its QUAD franchise."GILD closed at $49.31 a share yesterday.

27% profit every 20 days?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!